No CrossRef data available.
Article contents
Modelos de prescripción de antidepresivos en Europa: Resultados del estudio de los Factores que Influyen en la Investigación de los Criterios de Valoración de la Depresión (FINDER)
Published online by Cambridge University Press: 01 May 2008
Resumen
Los modelos de prescripción de antidepresivos y los factores que influyen en la elección del antidepresivo para el tratamiento de la depresión se estudiaron en el estudio de los Factores que Influyen en la Investigación de los Criterios de Valoración de la Depresión (FINDER), un estudio prospectivo de observación realizado en 12 países europeos con 3.468 adultos sobre el comienzo de la medicación antidepresiva en el primer episodio de depresión o en un nuevo episodio de depresión recurrente. Los inhibidores selectivos de la recaptación de serotonina (ISRS) son los antidepresivos más prescritos más frecuentemente (63,3% de los pacientes), seguidos de los inhibidores de la recaptación de serotonina-noradrenalina (IRSN, 13,6%), pero hubo una variación considerable entre los distintos países. Debemos destacar que se prescribieron antidepresivos tricíclicos y tetracíclicos (ATC) al 26,5% de los pacientes en Alemania. La elección del antidepresivo prescrito estaba bajo una influencia muy fuerte del uso anterior de antidepresivos, que se asoció considerablemente con la prescripción de un ISRS (CP 0,64; IC 95% 0,54, 0,76), un IRSN (CP 1,49; 1C 95% 1,18, 1,88) o una combinación de antidepresivos (CP 2,78; IC 95% 1,96, 3,96). Los factores del médico (edad, sexo, especialidad) y de los pacientes (gravedad de la depresión, edad, educación, tabaquismo, número de enfermedades físicas y síndromes funcionales actuales) se asociaron con la eleccción del antidepresivo inicial en algunos casos. Para concluir, la prescripción de antidepresivos varía en función del país, y el tipo de antidepresivo escogido está bajo la influencia de factores relacionados con el médico y con el paciente.
- Type
- Artículo original
- Information
- Copyright
- Copyright © European Psychiatric Association 2008
References
Bibliografía
[1]Agüera, LFRojo, JERos, Sde la Gándara, Jde Pedro, JM. Antidepressant combinations: epidemiological considerations. Acta Psychiatr Scand 2005; 112(Suppl. 428): 7–10.CrossRefGoogle Scholar
[2] American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revisión). Ara J Psychiatry 2000; 157(Suppl. 4): 1–45.Google Scholar
[3]Anderson, IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19–36.CrossRefGoogle ScholarPubMed
[4]Anderson, IMNutt, DJDeakin, JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: a revisión of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000; 14: 3–20.CrossRefGoogle ScholarPubMed
[5]Arroll, BMacgillivray, SOgston, SReid, ISullivan, FWilliams, B, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005; 3: 449-56.CrossRefGoogle ScholarPubMed
[6]Bauer, MBschor, TPfennig, AWhybrow, PCAngst, JVersiani, M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 2007; 8: 67–104.CrossRefGoogle ScholarPubMed
[7]Bauer, MWhybrow, PCAngst, JVersiani, MMoller, HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5–43.CrossRefGoogle ScholarPubMed
[8]Bauer, MWhybrow, PCAngst, JVersiani, MMoller, HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 2002; 3: 69–86.CrossRefGoogle ScholarPubMed
[9]Brooks, R, with the EuroQoL Group. EuroQol: the current State of play. Health Policy 1996; 37: 53–72.CrossRefGoogle ScholarPubMed
[10]Claxton, AJLi, ZMcKendrick, J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry 2000; 177: 163-8.CrossRefGoogle ScholarPubMed
[11]De la Gandara, JAgüera, LRojo, JERos, S, de Pedro JM. Use of antidepressant combinations: which, when and why? Results of a Spanish survey. Acta Psychiatr Scand 2005; 112(Suppl. 428): 32-6.CrossRefGoogle Scholar
[12] ESEMeD/MHEDEA 2000 Investigators. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004; 109(Suppl. 420): 55–64.Google Scholar
[13]Fegert, JMKolch, MZito, JMGlaeska, GJahnsen, K. Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 2006; 16: 197–206.CrossRefGoogle ScholarPubMed
[14]Furukawa, TAMcGuire, HBarbui, C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002; 325: 991–1000.CrossRefGoogle ScholarPubMed
[15]Garcia-Cebrian, ABauer, MMontejo, ALDantchev, NDemyttenaere, KGandhi, P, et al. Characteristics of depressed outpatients entering the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry 2008; 23: 57–65.CrossRefGoogle Scholar
[16]Guaiana, GAndretta, MCorbari, LMirándola, MSorio, AD’Avanzo, B, et al. Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. J Clin Psychiatry 2005; 66: 750-5.CrossRefGoogle ScholarPubMed
[17]Hansen, RAGartlehner, GLohr, KNGaynes, BNCarey, TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intem Med 2005:143:415-26.CrossRefGoogle ScholarPubMed
[18]Lawrenson, RATyrer, FNewson, RBFarmer, RD. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 2000; 59: 149-57.CrossRefGoogle ScholarPubMed
[19]MacGillivray, SArroll, BHatcher, SOgston, SReid, ISullivan, F, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003; 326: 1014-9.CrossRefGoogle ScholarPubMed
[20]Martin-Agueda, BLopez-Muñoz, FRubio, GGuerra, JASilva, AAlamo, C. Management of depression in primary care: a survey of general practitioners in Spain. Gen Hosp Psychiatry 2005; 27: 305-12.CrossRefGoogle ScholarPubMed
[21]Montejo, ALGilaberte, IFombellida, CHylan, TRSacristán, JA. Pattern of usage of new antidepressants in clinical practice. Actas Luso Esp Neurol Psiquiatr 1998; 26: 75–81 [in Spanish],Google ScholarPubMed
[22] National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline No. 23,; December 2004. Available from www.nice.org.uk [accessed 4.12.2007],Google Scholar
[23]Olie, JPElomari, FSpadone, CLepine, JP. Antidepressant consumption in the global population in France. Encephale 2002; 28: 411-7 [in French].Google ScholarPubMed
[24]Paykel, ESBrugha, TFryers, T. Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol 2005; 15: 411-23.CrossRefGoogle ScholarPubMed
[25]Peretti, SJudge, RHindmarch, I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2000; 102(Suppl. 403): 17–25.CrossRefGoogle Scholar
[26]Rush, AJTrivedi, MHWisniewski, SRStewart, JWNierenberg, AAThase, ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354: 1231-42.CrossRefGoogle ScholarPubMed
[27]Sclar, DARobison, LMSkaer, TLGalin, RS. What factors influence the prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters. Int J Psychiatry Med 1998; 28: 407-19.CrossRefGoogle ScholarPubMed
[28]Sleath, BShih, YC. Sociological influences on antidepressant prescribing. Soc Sci Med 2003; 56: 1335-44.CrossRefGoogle ScholarPubMed
[29]Stafford, RSMacDonald, EAFinkelstein, SN. National patterns of medication treatment for depression, 1987 to 2001. Primary Care Companion J Clin Psychiatry 2001; 3: 232-5.CrossRefGoogle ScholarPubMed
[30]Tylee, AGastpar, MLepine, JPMendlewicz, J. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. Int Clin Psychopharmacol 1999; 14: 139-51.Google Scholar
[31]Ufer, MMeyer, SAJunge, OSelke, GVolz, HPHedderich, J, et al. Patterns and prevalence of antidepressant drug use in the Germán State of Baden-Wuerttemberg: a prescription basad analysis. Pharmacoepidemiol Drug Saf 2007; 16: 1153-60.CrossRefGoogle Scholar
[32]Van Marwijk, HWBijl, DAder, HJde Haan, M. Antidepressant prescription for depression in general practice in The Netherlands. Pharm World Sci 2001; 23: 46-9.CrossRefGoogle ScholarPubMed
[33]Williams, JWMulrow, CDChiquette, EHitchcock, PAguilar, CCornell, J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132: 743-56.CrossRefGoogle ScholarPubMed
[34]Wohlreich, MMMartínez, JMMallinckrodt, CHPrakash, AWatkin, JGFava, M. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 2005; 25: 552-60.CrossRefGoogle ScholarPubMed
[35]Zetin, MHoepner, CTBjornson, L. Rational antidepressant selection: applying evidence-based medicine to complex real-world patients. Psychopharmacol Bull 2006; 39: 38–104.Google ScholarPubMed
[36]Zigmond, ASSnaith, RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.CrossRefGoogle ScholarPubMed
[37]Zimmerman, MMattia, JIPosternak, MA. Are subjects in pharmacological treatment triáis for depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159: 469-73.CrossRefGoogle Scholar
[38]Zimmerman, MPosternak, MFriedman, MAttiullah, NBaymiller, SBoland, R, et al. Which factors influence psychiatrists’ selection of antidepressants? Am J Psychiatry 2004; 161: 1285-9.CrossRefGoogle ScholarPubMed